TV’s Dr. Oz Invested in Businesses Regulated by Agency Trump Wants Him To Lead

President-elect Donald Trump’s choice to run the sprawling government agency that administers Medicare, Medicaid, and the Affordable Care Act marketplace — celebrity doctor Mehmet Oz — recently held broad investments in health care, tech, and food companies that would pose significant conflicts of interest. Oz’s holdings, some shared with family, included a stake in UnitedHealth…

Read More

THCB Gang Episode 145, Thursday November 21

Joining Matthew Holt (@boltyboy) on #THCBGang on Thursday November 21 at 1PM PT 4PM ET are regulars delivery & platform expert Vince Kuraitis (@VinceKuraitis) &  JL Neptune MD, now at Memora Health, digital health investment banker Steven Wardell (@StevenWardell); and longtime startup and corporate digital health exec Adam Kaufman (@adkaufman) who also writes the Bearing.on…

Read More

Health economic value of postacute oral nutritional supplementation in older adult medical patients at risk for malnutrition

That is my recent paper with co-authors Shanshan Wang, Jason Shafrin, and Kirk Kerr in BMJ Open. The abstract is below: Objective To estimate the health economic value of postdischarge oral nutrition supplement (ONS) consumption among elderly adults who were malnourished during hospitalisation. Design A cost-effectiveness model was developed from a US payer perspective based on a…

Read More

Washington Power Has Shifted. Here’s How the ACA May Shift, Too.

President-elect Donald Trump’s return to the White House could embolden Republicans who want to weaken or repeal the Affordable Care Act, but implementing such sweeping changes would still require overcoming procedural and political hurdles. Trump, long an ACA opponent, expressed interest during the campaign in retooling the health law. In addition, some high-ranking Republican lawmakers…

Read More

Speculation on RFK Jr. as HHS Secretary

From Tyler Cowen at Marginal Revolution: One of the problems with an RFK Jr. ascendancy is that his core views, which run strongly against vaccines and pharmaceuticals, make it unlikely that any of these reimbursement revisions will be done in a rational or scientific way. The best evidence indicates that pharmaceuticals are a relatively cost-effective ways of saving…

Read More